Additionally, Merck today announced it is now enrolling ... anti-tumor activity for the combination of tepotinib plus gefitinib compared with chemotherapy in patients with EGFR-mutant locally ...

In addition, the cost of gefitinib is "far ... consulted for or served in an advisory role with AstraZeneca, Roche, Merck, Boehringer Ingelheim; has received honoraria from AstraZeneca, Lilly ...

"The study exceeded our primary objective and demonstrated the superiority of gefitinib," said Dr. Fukuoka ... Pfizer, and/or Merck. Dr. Schilsky has no relevant financial relationships to ...

The plasma concentrations of gefitinib that can be achieved with ... fees from AstraZeneca and grant support from AstraZeneca, Merck, Genentech, Pharmacia, GlaxoSmithKline, Chiron, Bristol-Myers ...

Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point. The phase 3 trial found that adding chemotherapy to gefitinib improved ...

The targeted therapy gefitinib should be considered a first-line therapy for nonsmoking Asian patients with adenocarcinoma of the lung, one of the most common types of lung cancer, suggests a ...

Gefitinib, as compared with carboplatin–paclitaxel, was associated with a lower rate of grade 3 or 4 adverse events, as defined according to the Common Terminology Criteria for Adverse Events ...

Gefitinib (Iressa, AstraZeneca) is a selective inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) which blocks the signal pathways involved in cell proliferation. By blocking EGFR ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of gefitinib for locally advanced or metastatic NSCLC, having considered evidence on the nature of locally ...